Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HARMONY PLUS

Financiado

HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEM...

HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY PLUS Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be easily diagnosed nor treated. Nowadays most treatments are extremely complex, and advances... ver más

31/03/2024

FUNDACION INSTITUT...

12M€

Presupuesto del proyecto: 12M€

Líder del proyecto

FUNDACION INSTITUTO ESTUDIOS CIENCIAS DE LA S... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 11M€

Ver 49 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-03-31

IMI2-2019-19-01: Restricted Call to maximise impact...

I+D

Cerrada hace 5 años

0% 56% 100%

49 Participantes

FUNDACION INSTITUTO ESTUDIOS...

1.61M€ | Lider

AIRBUS DEFENCE AND SPACE

500.76K€ | Participante

AIRBUS OPERATIONS

285.57K€ | Participante

RAMEM

295.57K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 46 meses Fecha Inicio: 2020-05-26
Fecha Fin: 2024-03-31

Líder del proyecto

FUNDACION INSTITUTO ESTUDIOS CIENCIAS DE LA S... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 11M€

Presupuesto del proyecto 12M€

Descripción del proyecto Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be easily diagnosed nor treated. Nowadays most treatments are extremely complex, and advances in patient diagnosis and therapies slow due to the low number of patients per centre. Thus, there is a need to harmonise, store, and analyse the current HM information to speed-up and support the decision-making process for patients’ access to new therapies. HARMONY PLUS takes advantage of the capabilities of the HARMONY Big Data platform to match these unmet needs by expanding its scope to incorporate myeloproliferative neoplasms, including chronic myeloid leukemia, polycythaemia vera, essential thrombocythaemia, and myelofibrosis; and lymphoproliferative disorders, including Hodgkin’s lymphoma, Waldenström macroglobulinemia and all the other rare HMs not covered by HARMONY Project. In parallel, HARMONY PLUS will continue to refine and define the Core Outcome Sets (COS), especially for these new HMs to ensure the use by researchers of useful common outcomes relevant to all stakeholders. As previously accomplished in HARMONY, HARMONY PLUS is committed to pursue the maximum ethical and legal requirements, particularly to ensure patient’s right to privacy. Data-driven research within Europe will be enhanced by converting the current HARMONY platform into an Integrated Services Platform to serve as a valuable tool to support clinical trial design and use of available data as a control arm. This platform, combined with a HaemoDatabank repository with information about HMs patient biological samples across Europe, will facilitate a more efficient research and clinical trial design, and consequently will promote collaborations with recognised databases outside Europe. From the regulatory point of view, HARMONY PLUS will be a valuable technology tool during the evaluation of new treatments and drugs by also considering the patients’ needs.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores